Back to Search
Start Over
P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms
- Source :
- BMC Cancer, Vol 20, Iss 1, Pp 1-14 (2020), Nielsen, K, Binderup, T, Langer, S W, Kjaer, A, Knigge, P, Grøndahl, V, Melchior, L, Federspiel, B & Knigge, U 2020, ' P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms ', BMC Cancer, vol. 20, 27 . https://doi.org/10.1186/s12885-019-6498-z, BMC Cancer
- Publication Year :
- 2020
- Publisher :
- BMC, 2020.
-
Abstract
- Background High grade gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) with a Ki67 proliferation index > 20%, include well-differentiated tumours grade 3 (NET G3) and poorly differentiated (PD) neuroendocrine carcinomas (NEC). Abnormal p53-expression is a feature of PD tumours, while expression of chromogranin A (CgA) and somatostatin-receptor 2a (SSTR-2a) may be a feature of well-differentiated tumours. The aim of this study was to elucidate the expression and prognostic value of these three markers in 163 GEP-NEN patients with a Ki67-index > 20%. Method Clinical data, histopathology and overall survival were analysed according to Kaplan-Meier’s method and Cox regression. The expression of SSTR-2a, CgA and synaptophysin was analysed in tumour specimens by immunohistochemistry, and semi-quantitatively scored as negative ( 30%). P53 was defined as normal when scored as heterogeneously positive (1–30%), and abnormal when negative (0%) or strongly positive (> 30%). Results In multivariate analysis, better survival was observed among patients with heterogeneously positive p53 compared to strongly positive (p p = 0.002). Survival was significantly worse for negative CgA compared to heterogeneously positive CgA (p = 0.02). Strongly positive SSTR-2a expression was found in 26% of the 163 included patients. Well-differentiated morphology correlated with strong expression of SSTR-2a and CgA, and heterogeneously positive p53-staining, and was more frequent in pancreatic primaries. In pancreatic primaries, strongly positive SSTR-2a was associated with longer survival (univariate analysis, p = 0.02). A significantly lower Ki67 proliferation index was found in patients with a heterogeneously positive p53, a positive SSTR-2a and CgA expression. Conclusion Our results suggest that abnormal p53-expression is an independent negative prognostic marker in GEP-NEN with a Ki67-index > 20%. Patients with heterogeneously positive p53 had the best prognosis. SSTR-2a was a positive prognostic marker in pancreatic NEN. Negative CgA was associated with a significantly worse OS compared to heterogeneously positive CgA-expression in a multivariate sub-analysis. Lower Ki67 index correlated significantly with heterogeneously positive p53, positive SSTR-2a and CgA expression.
- Subjects :
- 0301 basic medicine
Male
p53
Cancer Research
Survival
Proliferation index
Gastroenteropancreatic neuroendocrine neoplasms
Prognostication
Gastroenterology
0302 clinical medicine
Surgical oncology
Receptors, Somatostatin
Gastrointestinal Neoplasms
Aged, 80 and over
biology
Chromogranin A
Middle Aged
Prognosis
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Immunohistochemistry
Oncology
030220 oncology & carcinogenesis
Female
Research Article
Adult
endocrine system
medicine.medical_specialty
Carcinoma, Neuroendocrine/diagnosis
Gastrointestinal Neoplasms/diagnosis
lcsh:RC254-282
Neuroendocrine carcinomas
03 medical and health sciences
Young Adult
Internal medicine
Cell Line, Tumor
mental disorders
Genetics
medicine
Biomarkers, Tumor
Humans
Pancreatic Neoplasms/diagnosis
Tumor Suppressor Protein p53/metabolism
Aged
Proportional Hazards Models
Chromogranin A/metabolism
business.industry
Proportional hazards model
NEC
Somatostatin receptor 2a
Carcinoma, Neuroendocrine
Receptors, Somatostatin/metabolism
Pancreatic Neoplasms
030104 developmental biology
biology.protein
Synaptophysin
Histopathology
Tumor Suppressor Protein p53
Neoplasm Grading
NET G3
business
Immunostaining
Follow-Up Studies
Subjects
Details
- Language :
- English
- ISSN :
- 14712407
- Volume :
- 20
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- BMC Cancer
- Accession number :
- edsair.doi.dedup.....9d93255a464ae954445e87947288cacf
- Full Text :
- https://doi.org/10.1186/s12885-019-6498-z